Investment Rating - The report does not explicitly state an investment rating for the industry, but it suggests a positive outlook for the medical device sector, indicating potential for growth and innovation [2][3]. Core Insights - The medical device sector is expected to enter a "great sailing era" with the initiation of centralized procurement for drug-coated balloons and urological intervention consumables, indicating a significant policy shift that could benefit domestic manufacturers [3]. - The report highlights that after extensive centralized procurement, domestic medical device manufacturers have gained substantial market share, leading to a concentration of the industry towards leading enterprises, which are expected to benefit from scale effects and favorable export policies [3]. - The report emphasizes the potential for domestic medical device companies to replicate the path of domestic pharmaceutical companies, using centralized procurement to drive innovation and enhance global competitiveness [3]. Market Weekly Review - The pharmaceutical and biotechnology sector experienced a slight decline of 0.18% from December 22 to December 26, underperforming compared to the Wind All A index (2.78%) and the CSI 300 index (1.95%) [8]. - Among sub-sectors, raw materials (2.05%), blood products (1.28%), and medical research outsourcing (0.77%) showed gains, while hospitals (-2.82%), pharmaceutical distribution (-1.8%), and offline pharmacies (-1.3%) faced declines [8]. - Notable individual stock performances included Hongyuan Pharmaceutical (59.4%), Luyuan Pharmaceutical (37.3%), and Huakang Medical (21.1%) with significant gains, while ST Bailin (-18.5%), Huaren Health (-15.8%), and Haiwang Biological (-14.9%) saw substantial losses [11]. Industry News and Key Company Announcements - The National Medical Products Administration announced new regulations for the management of medical device export sales certificates, effective May 1, 2026, which aims to facilitate the export of Chinese medical devices [13]. - The centralized procurement for high-value medical consumables has officially started, marking a significant policy development in the industry [13]. - Sanofi reached an acquisition agreement with Dynavax for $2.2 billion, highlighting ongoing consolidation in the pharmaceutical sector [13]. - Notable collaborations and agreements were reported, including licensing agreements and partnerships among various pharmaceutical companies, indicating active M&A and collaboration trends in the industry [16][17].

医药生物 2025 年 12 月 29 日 版 行业 《本周申万医药生物指数下跌 0.1%，关注 国内药企出海动态——医药行业周报 (2025/12/15-2025/12/19)》 2025/12/22 《本周申万医药生物指数下跌 1.0%，关注 创新药对外授权动态——医药行业周报 (2025/12/08-2025/12/12) 》 2025/12/14 证券分析师 张静含 A0230522080004 zhangjh@swsresearch.com 陈田甜 A0230524080013 chentt@swsresearch.com 联系人 陈田甜 A0230524080013 chentt@swsresearch.com 申万宏源研究微信服务号 0.2%,关注对外授权及新品上 —— 医药行业周报（2025/12/22-2025/12/26） 本期投资后示 请务必仔细阅读正文之后的各项信息披露与声明 本 周 申 万 医 药 生 物 指 数 下 看好 相关研究 市场表现：本周申万医药生物指数下跌 0.2%，同期上证指数上涨 1.88%，万得全 A ● (除金融石油石化） 上涨 3.1%。本周医药生物指数在 31 ...

证券研究报告 2025 年 12 月 28 日 湘财证券研究所 行业研究 医疗耗材行业周报 第六批耗材集采启动，关注后续开标情况 相关研究： | 1. 《第五批耗材国采即将落地执 | | --- | | 行》 2025.02.18 | | 2.《年报披露密集期，耗材板块关 | | 注创新与业绩修复》 2025.04.01 | 行业评级：增持（维持） 近十二个月行业表现 -50.00% 0.00% 50.00% 沪深300 医疗耗材 | % | 1 个月 | 3 个月 | 12 个月 | | --- | --- | --- | --- | | 相对收益 | -3 | -8 | -9 | | 绝对收益 | -1 | -7 | 8 | 注：相对收益与沪深 300 相比 分析师：聂孟依 证书编号：S0500524040001 Tel：(8621) 50299667 Email：nmy06967@xcsc.com 地址：上海市浦东新区银城路 88 号 中国人寿金融中心 10 楼 核心要点： ❑ 医疗耗材板块上周上涨 0.08% 根据 wind，上周，医药生物报收 8254.26 点，下跌 0.18%，涨幅排名位列 申万 ...

智通财经获悉，国泰海通发布研报称，第六批耗材国采文件发布，此次集采分AB单元进行多轮报价， 价格降幅预期温和，保量情况符合预期，国产厂商市占率有望提升。维持医药行业"增持"评级。推荐有 望受益集采落地带动销售放量的耗材企业。 国泰海通主要观点如下： 风险提示：手术量不及预期，集采执行时间不及预期，产品价格波动风险等。 股票频道更多独家策划、专家专栏，免费查阅>> 责任编辑：栎树 事件：12月22日，国家组织高值医用耗材联合采购办公室关于发布《国家组织药物涂层球囊类、泌尿介 入类医用耗材集中带量采购文件(GH-HD2025-1)》的公告，第六批耗材国采将于2026年1月13日上午9:30 现场公开申报信息，此次集中带量采购周期自联盟各地区中选结果实际执行日起至2028年12月31日。原 则上每年度总协议采购量不低于前一年总实际使用量的90%，各中选企业每年度协议采购量不低于同中 选企业上年协议采购量。 分AB单元进行多轮报价，预期价格降幅温和。本次集中带量采购各品种按竞价单元开展竞价，A、B竞 价单元的同一竞价单元内，依据企业申报价格及折算规则计算竞价比价价格后开展竞价比价，由低到高 排名，确定入围企业。入围企 ...

Core Viewpoint - The sixth batch of high-value medical consumables centralized procurement documents has been released, with expectations of moderate price reductions and an increase in market share for domestic manufacturers [1][2]. Group 1: Event Overview - On December 22, the National Organization for High-Value Medical Consumables Joint Procurement Office announced the release of procurement documents for drug-coated balloons and urological intervention consumables, with the sixth batch set to begin on January 13, 2026 [2]. - The procurement cycle will last until December 31, 2028, with total annual agreement procurement volumes not less than 90% of the previous year's actual usage [2]. Group 2: Pricing and Bidding Process - The procurement will be conducted in multiple rounds of bidding divided into A and B units, with expectations of moderate price declines [2]. - Bidding will be based on the declared prices and a pricing comparison rule, ranking from low to high to determine the selected enterprises [2]. Group 3: Market Impact - The volume of procurement is in line with expectations, and there is potential for an increase in market share for domestic manufacturers [3].

Macro Research - The core viewpoint of the report indicates that the US economy showed resilience in Q3 2025, with a GDP growth rate of 4.3%, surpassing expectations of 3.3% and the previous value of 3.8% [3][20] - Key drivers of this resilience include strong personal consumption, increased public spending, and enhanced export contributions, with capital market wealth effects supporting consumer spending [3][20] - The report highlights a "K" shaped economic divergence, characterized by income disparities affecting consumption, varying business conditions between large and small enterprises, and differences in investment growth between new and old economies [4][21] Strategy Research - The report emphasizes that Chinese companies are entering a new phase of globalization, aiming to capture high-value segments of the global value chain [9][25] - It notes that the acceleration of Chinese enterprises going abroad is a strategic response to rising domestic costs and tightening external market access, which is essential for high-quality development [9][25] - The report predicts that the demand for capital goods in China will remain strong, driven by industrialization and infrastructure investment in emerging markets [11][27] Biopharmaceutical Research - The report discusses the release of the sixth batch of medical device procurement documents, indicating a moderate expected price drop and a favorable situation for domestic manufacturers to increase market share [13][29] - It provides specific data on the expected demand for various medical devices, highlighting the market shares of different companies in the procurement process [30][32] - The report maintains a "buy" rating for companies likely to benefit from the procurement, such as Lepu Medical and Mindray Medical [29][30]

Macro Analysis - The US GDP growth rate for Q3 2025 is 4.3%, exceeding expectations of 3.3% and the previous value of 3.8%, indicating strong economic resilience [3] - Key drivers of this resilience include robust personal consumption, increased public spending, and enhanced export contributions [3] - Personal consumption is supported by the wealth effect from capital markets, with major stock indices reaching historical highs in Q3 2025 [3] - Government spending, particularly in defense, and investments in companies like Intel have also contributed to economic strength [3] - A recovery in global economic activity has boosted US exports, aided by trade agreements that have reduced or eliminated tariffs [3] K-Shaped Recovery - The US economy exhibits a "K" shaped recovery, characterized by income and consumption disparities [4] - Income inequality has been exacerbated by policies affecting the job market, leading to higher unemployment rates among minority groups [4] - Large enterprises are faring better than small businesses, as indicated by the S&P Global Composite PMI remaining above the neutral line, while the NFIB small business optimism index has declined [4] - Investment and growth disparities are evident, with strong performance in private non-residential investments, particularly in equipment and intellectual property, while construction investment growth has slowed [4] Future Economic Outlook - The US government shutdown from October 1 to November 12, 2025, is expected to impact Q4 2025 economic performance, but resilience is anticipated in 2026 [5] - The shutdown will reduce government procurement and investment activities, affecting economic performance directly and indirectly [5] - A recovery in Q1 2026 is likely due to pent-up demand and continued strength in consumption and new economic investments [5] - The Federal Reserve is expected to lower interest rates 2-3 times in 2026, despite a strong economy, due to structural weaknesses in the labor market [5] Globalization of Chinese Enterprises - Chinese enterprises are entering an accelerated phase of globalization, driven by the need to occupy high-value segments of the global supply chain [9] - The transition from a GDP-driven growth model to a GNI-driven model emphasizes innovation and accelerated globalization [9] - China's trade competitiveness has improved significantly, particularly in capital and technology-intensive sectors, with exports exceeding expectations since 2025 [10] - Chinese companies are shifting from product exports to a more integrated approach involving capacity, branding, and distribution [10] Capital Expenditure Trends - A global upturn in industrial and infrastructure capital expenditure is expected, driven by easing monetary policies and increased demand in emerging markets [11] - Southeast Asian countries are experiencing rapid industrialization and urbanization, leading to significant demand for power and infrastructure [11] - Developed markets are also seeing a surge in demand for energy infrastructure updates due to green transitions and AI-driven needs [11] - The resilience of overseas demand for Chinese products is projected to exceed market expectations in 2026 [11] Industry Recommendations - Recommended sectors include power equipment, machinery, automotive, new materials, innovative pharmaceuticals, and gaming [12] - Emerging market industrialization is expected to drive demand for power and infrastructure, while developed markets will continue to update energy infrastructure [12] - High-value components are recommended due to China's technological and cost advantages, with a focus on communication equipment and automotive parts [12] - The urbanization in emerging markets is anticipated to create new demand for consumer products, enhancing the global presence of Chinese cultural and service sectors [12]

Macroeconomic Overview - The U.S. GDP growth for Q3 exceeded expectations, with an initial annualized rate of 4.3%, compared to a forecast of 3.3% and a previous quarter's final value of 3.8% [4] - Personal consumption expenditures rose from 2.5% in Q2 to 3.5% in Q3, surpassing the expected 2.7% [4] - Exports increased significantly by 8.8%, while imports decreased by 4.7% [4] Industry Insights Precious Metals - International gold and silver prices reached historical highs, with COMEX gold futures at $4,515 per ounce (up 1.02%) and silver at $71.61 per ounce (up 4.44%) [7] - The rise in precious metals prices is attributed to market expectations of continued interest rate cuts by the U.S. government [7] Medical Supplies - The sixth batch of high-value medical consumables procurement has been officially launched, including drug-coated balloons and urological intervention consumables, with bidding set for January 13, 2026 [8] - The introduction of anchor pricing and a multi-repetition mechanism is expected to prevent malicious competition, although significant price declines are anticipated [8] Automotive Industry - Retail data for January-November 2025 shows that major brands like BYD, Volkswagen, and Toyota dominate the market, with the top ten brands holding a combined market share of 51.7% [10] - The competitive landscape remains fragmented, with ongoing price wars likely due to the lack of a dominant market structure [10] - Demand resilience in the battery supply chain is noted, but profitability will depend on product structure and bargaining power [10] Air Conditioning Sector - The air conditioning industry experienced a significant decline in production and sales in November, with production and sales down approximately 37% and 32% year-on-year, respectively [12] - The decline is attributed to high base effects from previous government subsidy policies and abnormal weather conditions [12] - A cautious outlook is maintained for the industry, with production plans for January 2026 indicating a year-on-year increase of about 21% [12]

昨日A股 12月23日，市场冲高回落，三大指数一度集体翻绿，创业板指盘中涨超1%。截至收盘，沪指涨0.07%， 深成指0.27%，创业板指0.41%。沪深两市成交额1.9万亿，较上一个交易日放量379亿。 全市场近3900只个股下跌。从板块来看，海南自贸概念局部强势，锂电池板块走强，液冷服务器午后拉 升，半导体设备概念反复活跃，有色·钨概念表现活跃。下跌方面，商业航天概念冲高回落，旅游概念 多股下挫。板块方面，光刻机、电池、海南自贸区等板块涨幅居前，旅游及酒店、商业航天等板块跌幅 居前。 欧洲三大股指12月23日涨跌不一。截至当天收盘，英国富时100种股票平均价格指数23日报收于9889.22 点，较前一交易日上涨23.25点，涨幅为0.24%。法国巴黎股市CAC40指数报收于8103.85点，较前一交 易日下跌17.22点，跌幅为0.21%；德国法兰克福股市DAX指数报收于24340.06点，较前一交易日上涨 56.09点，涨幅为0.23%。 国际油价12月23日微涨。截至当天收盘，纽约商品交易所2026年2月交货的轻质原油期货价格上涨37美 分，收于每桶58.38美元，涨幅为0.64%；2月交货的伦敦布伦 ...

【隔夜行情】 •周二（2025年12月23日），A股市场三大指数集体收涨，截至收盘，沪指报3919.98点，涨0.07%；深证 成指报13368.99点，涨0.27%；创业板指报3205.01点，涨0.41%。总体来看，个股跌多涨少，下跌个股 超3800只。沪深两市全天成交额1.90万亿元，较上个交易日放量379亿元。 •周二（2025年12月23日），港股三大指数盘中集体翻绿。截止收盘，恒生指数跌0.11%或27.63点，报 25774.14点，全日成交额为1571.31亿港元；恒生国企指数跌0.29%，报8913.83点；恒生科技指数跌 0.69%，报5488.89点。 •周二（当地时间2025年12月23日），美股三大指数涨跌不一，截至收盘，道琼斯指数涨0.61%，报 47716.42点；标普500指数涨0.54%，报6849.09点；纳斯达克综合指数涨0.65%，报23365.69点。 【今日新股】 今日1只新股上市，无新股申购。 新股上市： 健信超导，科创板证券代码688805，发行价格18.58元/股，发行市盈率61.97倍；公司是全球医用磁共振 成像（MRI）设备核心部件领域的领军企业，主要从事 ...